I am the CEO of ProVascTec, a cell therapy company that combines biomedical engineering with cell therapies to enable intracorporal precision delivery of cells
We are a team of cell biologists, medical doctors, and entrepreneurs, with a vision to enable the delivery of a cellular payload to any site of medical need. Past attempts to broadly apply cell therapies have failed to deliver. Key obstacles have been the absence of scalable allogeneic cell sources, effective cell delivery, payload size, and rapid cells death upon delivery. Our solution aims to be the first breakthrough therapy combining cells with a biodegradable device that can be delivered through the vasculature to any site in the body. Moreover, specific design modifications would allow similar biodegradable devices to be delivered by minimally invasive endoscopic approaches to any organ in the body including in the broad fields of inflammation, cancer and other age related diseases.
I am the CEO and co-founder of ProVascTec. Following an education in chemistry, which concluded with a PHD from the Swiss Federal Institute of Technology, Holger started his professional career at Bain & Company, a leading international strategic management consultancy. He later joined Novartis, where he was leading several innovation projects at various stages of the product lifecycle. Following a 10 year career at Novartis, Holger joined Cell Medica as SVP Commercial Operations, a cell therapy company focused on immunological- and hematological applications. Subsequently, Holger held additional c-level positions at startup companies in Switzerland before joinging ProVascTec in 2013.